STAT

APRIL 12, 2024

Now, a new study, published Thursday in JAMA Network Open , demonstrates that those benefits can extend longer and be even more effective than some clinical therapies in dealing with lower back pain, which affects half of the U.S. population in any given year.

132

132

Board Vitals - Pharmacist

MARCH 15, 2024

Explore the Positives Take some time to research the program you’ve matched into. Look for unique opportunities, such as research projects, clinical experiences, or mentorship programs, that could enrich your residency experience and turn a negative into a positive.

Medical Schools 105

Medical Schools 105

STAT

JUNE 6, 2023

But it’s not a path equally open to everyone. graduates who have started families or have big loans, or are Black or female, say they plan to pursue postdoc positions at lower rates than their peers, according to a STAT analysis that includes previously unreported data from the National Center for Science and Engineering Statistics.

122

122

Drug Store News

OCTOBER 4, 2022

According to a report, the company is set to close all job openings for corporate positions in its retail divisions.

110

110

STAT

OCTOBER 11, 2023

Then, after discharge, she and her husband chose to exercise that right: She was pregnant, uninsured, in a mental health crisis, and in no position to have a kid. That was partially why she started volunteering outside an abortion provider’s office in Bristol, Tenn.

145

145

Pharmafile

JANUARY 10, 2024

The trial was a 52-week, open-label treat-to-target trial which assessed the efficacy and safety of once-weekly IcoSema compared to once-daily insulin glargine U100 and insulin aspart (injected 2-4 […] The post Novo Nordisk shares positive results from COMBINE 3 phase 3a trial appeared first on Pharmafile.

Labelling 58

Labelling 58

Board Vitals - Pharmacist

MARCH 10, 2024

During the 2023 Main Residency Match , there were 42,952 applicants with only 37,425 positions available. There are simply not enough open positions to meet the growing demand among medical students. The SOAP window opens at 12:00 PM EST the Monday of Match Week and closes at 3:00 PM EST on the Thursday of Match Week.

Medical Schools 98

Medical Schools 98

Pharma Marketing Network

OCTOBER 16, 2023

It means that companies must be open and honest in their communication with customers, and provide them with clear and accurate information. By providing customers with access to this information, companies can demonstrate their commitment to being open and honest with their customers.

Customer Service 52

Customer Service Communication 52

European Pharmaceutical Review

DECEMBER 4, 2023

It is also the only C5 inhibitor approved for self-administration by adult patients who are AChR antibody-positive with this disease. Generalised myasthenia gravis patients who completed the RAISE trial had the option to take part in the open-label RAISE-XT extension study, UCB stated.

Labelling 98

Labelling 98

STAT

AUGUST 24, 2023

The news that the weight loss drug Wegovy reduced the risk of heart attacks and strokes in overweight volunteers opens up the door to vastly expanded use of the drug and medicines like it, known as GLP-1 inhibitors.

Pharmaceutical Companies 83

Pharmaceutical Companies Pharmaceutical Companies 83

STAT

MARCH 31, 2023

But what biological factors contribute to these disparities – and how much – is an open question. Within breast cancer subtypes, Black patients tend to have worse outcomes compared to white negative patients, too. Read the rest…

Chemotherapy 109

Chemotherapy 109

European Pharmaceutical Review

MAY 24, 2023

Representation formats, such as the Business Process Model and Notation (BPMN) and the Laboratory Open Protocol (LabOP) were highlighted in the paper. Most importantly, the positions for arm control must be stored in a standardised fashion (encoded in the DT) and provided with the device out-of-the-box.

78

78

European Pharmaceutical Review

DECEMBER 5, 2022

PSMAfore, is a Phase III, open-label, multi-centre, 1:1 randomised study comparing the efficacy and safety of Pluvicto to a change in ARPI in 469 patients with PSMA–positive mCRPC. Pluvicto for PSMA–positive metastatic castration-resistant prostate cancer. The PSMAfore study.

Chemotherapy 98

Chemotherapy Compounding Labelling FDA 98

European Pharmaceutical Review

JANUARY 11, 2024

Ustekinumab biologic Once the European Supplementary Protection Certificate (SPC) for Stelara expires in July 2024, this will open up market entry as soon as possible for Uzpruvo, now that it is approved in Europe” Ustekinumab is a human IgG1κ monoclonal antibody (mAb). The EU ustekinumab market is worth €2.5

Immunization 100

Immunization 100

Find Your Script

MAY 25, 2022

Enter pharmacy school open-minded about the opportunities and people you will meet. You will then be set-up to run for leadership positions as a P2 student. Get a Pharmacist Internship position. You can also consider a specialized Intern Pharmacist position as a Summer Internship Program. Aim for a positive trend.

Community Pharmacies 130

Community Pharmacies Documentation Hospitals FDA 130

STAT

APRIL 18, 2024

While tavapadon doesn’t appear to be the key drug AbbVie focused on its acquisition, the new positive results still represent a win for the pharma company as it completes the deal. biotechs from doing business with the Chinese behemoth , STAT says. Continue to STAT+ to read the full story…

91

91

Pharmafile

MARCH 31, 2023

The device is the newest in Abbott’s Epic surgical valve platform which the company has been developing for decades with positive results. This can lead to fatal heart failure, stroke and blood clots. read more

FDA 63

FDA Communication 63

Pharmaceutical Technology

JUNE 29, 2022

The proportion of pharmaceutical companies hiring for AI related positions kept relatively steady in May 2022 compared with the equivalent month last year, with 39.3% of the companies included in our analysis recruiting for at least one such position. in April 2022. in April 2022.

Pharmaceutical Companies 110

Pharmaceutical Companies Pharmaceutical Companies 110

STAT

APRIL 17, 2024

Have a wonderful day, and please do stay in touch… Eli Lilly reported positive results for its obesity drug Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market , STAT tells us. Remember that no prescription is required.

Insurance Coverage 77

Insurance Coverage FDA Insurance 77

pharmaphorum

NOVEMBER 22, 2020

Rob Barker has been promoted to chief executive officer of Marlow, UK-based OPEN Health Group after serving as CEO of its Medical Communications practice for the last five years. Barker (pictured above) said: “I am excited to be leading such a talented and expert team who have been instrumental in growing OPEN Health to its current position.

Communication 78

Communication 78

STAT

OCTOBER 4, 2023

If you tested positive on the FM/a Test, advertising said, you could be eligible for a fibromyalgia treatment study. General before the research could get off the ground, even while his company continued to promote it as an opportunity open to those who’d taken the test.

Insurance 119

Insurance Hospitals 119

Pharmacy Is Right For Me

DECEMBER 14, 2023

Nevertheless, he wouldn’t trade his position for anything, reflecting, “Despite this negative side of my position, I am also proud to be part of team that has saved so many lives—sometimes against all odds—and given families healing and hope.” Helping children and their families is a passion for Dr.

Hospitals 162

Hospitals 162

STAT

JUNE 7, 2023

While other states and nations came to the global BIO 2023 convention in Boston this week on the hunt for investors and companies to grow their biotech sectors, Massachusetts has a different problem: It can’t find enough workers to fill positions.

75

75

European Pharmaceutical Review

JANUARY 19, 2024

An important advance in treating breast cancer The pharmaceutical company shared that its oral small molecule poly (ADP-ribose) polymerase (PARP) inhibitor is indicated in adults who have had an anthracycline or a taxane, or both, if suitable, and endocrine therapy in patients with hormone receptor (HR)-positive breast cancer, if suitable.

Chemotherapy 85

Chemotherapy Pharmaceutical Companies Pharmaceutical Companies Labelling 85

Pharmacy Is Right For Me

JANUARY 3, 2024

Versatility in Pharmacy Clinical pharmacists occupy a distinctive position, often granted patient care privileges that allow them to engage in comprehensive medication decision-making functions as integral members of the healthcare team. ¹ However, job opportunities opened up that provided me with valuable clinical experience.

Insurance 306

Insurance Communication Patient Care 306

Hospital Pharmacy Europe

SEPTEMBER 26, 2023

‘Serious and ongoing’ delays to FtP cases In the review, the PSA confirmed it has escalated concerns to the Department of Health and Social Care (DHSC) regarding ‘serious’ and ‘ongoing’ delays to the time taken by the GPhC to process FtP cases, and an increasing number of older cases that remain open.

Documentation 105

Documentation Hospitals 105

European Pharmaceutical Review

APRIL 30, 2024

Improving spectroscopic analysis Positively, the team were able to use acoustic waves to modulate this temporal overlap randomly. However, the main challenge has been to change the temporal overlap of the probe pulses and the femtosecond excitation pulses randomly,” Scheffter commented.

Labelling 77

Labelling 77

pharmaphorum

JULY 15, 2022

The FDA approval was based on results from two multicentre, open-label trials – ADVL0912 and A8081013 – that included 14 children and seven adults, respectively with unresectable, recurrent, or refractory ALK-positive IMT.

FDA 113

FDA Chemotherapy Labelling 113

Pharmaceutical Technology

JULY 25, 2022

The proportion of pharmaceutical companies hiring for machine learning related positions rose in June 2022 compared with the equivalent month last year, with 26.4% of the companies included in our analysis recruiting for at least one such position. This latest figure was higher than the 24.1% in May 2022. in May 2022.

Pharmaceutical Companies 93

Pharmaceutical Companies Pharmaceutical Companies 93

Pharmaceutical Technology

MAY 16, 2023

Byondis CEO Marco Timmers stated: “We continue to believe that SYD985 can present a meaningful treatment option for patients living with HER2-positive metastatic breast cancer. “We The application was supported by the findings from the multi-centre, open-label, randomised, pivotal Phase III TULIP clinical trial.

FDA 52

FDA Labelling 52

European Pharmaceutical Review

FEBRUARY 3, 2023

Switzerland-based contract development and manufacturing organisation (CDMO) CARBOGEN AMCIS has opened a new facility in France, dedicated to the custom development and production of sterile injectable drug products. Positively, it comes at a time when securing fill finish capacity can be a challenge for many pharmaceutical companies.

Dosage 93

Dosage Compounding Pharmaceutical Companies Pharmaceutical Companies 93

European Pharmaceutical Review

JANUARY 18, 2024

This position in the UK contrasts with the approximate 10 percent decline in ongoing global ATMP clinical trials that were observed from January to December 2023 (Alliance for Regenerative Medicine). This is largely due to the number of ongoing ATMP clinical trials in the UK remaining “largely stable” over the past three years.

99

99

Hospital Pharmacy Europe

SEPTEMBER 7, 2023

The use of adjunctive alectinib reduced disease recurrence in the early setting for people with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) compared to platinum-based chemotherapy, its manufacturer Roche has announced.

Chemotherapy 52

Chemotherapy Labelling Hospitals 52

Pharmaceutical Technology

NOVEMBER 25, 2022

Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted approval for Daiichi Sankyo ’s Enhertu (trastuzumab deruxtecan) to treat HER2-positive unresectable or recurrent breast cancer in adults. The treatment is indicated for usage in such patients following previous chemotherapy, comprising trastuzumab and a taxane.

Adverse Reactions 105

Adverse Reactions Chemotherapy Labelling 105

The Guardian - Pharmaceutical Industry

AUGUST 7, 2022

Just consider the sheer number of public figures – from Robbie Williams and Lady Gaga to Baroness Davidson – who have opened up about their struggles.

98

98

Pharmaceutical Technology

MAY 31, 2023

Repotrectinib is a tyrosine kinase inhibitor (TKI) intended to treat patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). The NDA was based on data from the first-in-human, open-label, global, multi-centre TRIDENT-1 trial.

FDA 52

FDA Labelling 52

Pharmaceutical Technology

FEBRUARY 27, 2023

China’s National Medical Products Administration (NMPA) has granted approval for Daiichi Sankyo and AstraZeneca ’s Enhertu (trastuzumab deruxtecan) to treat HER2-positive metastatic breast cancer. Being jointly developed and commercialised by the two companies, it is a specifically engineered HER2-directed antibody-drug conjugate (ADC).

Adverse Reactions 52

Adverse Reactions Labelling 52